Advertisement Genaera's Q3 net loss narrows - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Genaera’s Q3 net loss narrows

Genaera, a biopharmaceutical company, has reported a net loss of $3.4 million, or $(0.19) per basic and diluted share, for the three-month period ended September 30, 2008 as compared to a net loss of $3.7 million, or $(0.21) per basic and diluted share, for the three-month period ended September 30, 2007.

The net loss for the nine-month period ended September 30, 2008 was $12.4 million, or $(0.71) per basic and diluted share, as compared to a net loss of $9.9 million, or $(0.57) per basic and diluted share, for the nine-month period ended September 30, 2007.

The company has reported revenues of $92,000 for the three-month period ended September 30, 2008 as compared to $51,000 for the corresponding period of 2007.
For the nine-month period ended September 30, 2008, the company posted revenues of $1.44 million as compared to $2.6 million for the same period of 2007.